单次高剂量声带内注射曲弗明治疗年龄相关性声带萎缩的语音改善的一年结果和纵向变化

IF 2.4 4区医学 Q1 AUDIOLOGY & SPEECH-LANGUAGE PATHOLOGY

Journal of Voice Pub Date : 2025-09-01 DOI:10.1016/j.jvoice.2023.03.017

Tomohiro Hasegawa , Takeharu Kanazawa , Daigo Komazawa , Ujimoto Konomi , Mayu Hirosaki , Yusuke Watanabe

{"title":"单次高剂量声带内注射曲弗明治疗年龄相关性声带萎缩的语音改善的一年结果和纵向变化","authors":"Tomohiro Hasegawa , Takeharu Kanazawa , Daigo Komazawa , Ujimoto Konomi , Mayu Hirosaki , Yusuke Watanabe","doi":"10.1016/j.jvoice.2023.03.017","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><div>Although intracordal trafermin injection has been performed in the treatment of age-related vocal fold atrophy, the effects of single high dose trafermin injections are unknown. In this study, we examined the 1 year outcomes and longitudinal changes in voice improvement with single high dose intracordal trafermin injections.</div></div><div><h3>Study Design</h3><div>Retrospective study with approval by our Ethics Committee.</div></div><div><h3>Methods</h3><div><span>The medical records of 34 patients who underwent single high dose (50ug per side) intracordal trafermin injections under </span>local anesthesia for vocal fold atrophy were retrospectively reviewed at 1 month pre-injection and 1 month, 6 months and 1 year post injection.</div></div><div><h3>Results</h3><div><span>Maximum phonation time (MPT), pitch range (PR), Japanese version of voice handicap index (VHI), grade of </span>GRBAS evaluation, and jitter% improved significantly at 1-year post-injection compared to 1-month pre-injection. MPT and PR improved as early as 1-month post-injection and continued to improve most at 1-year post-injection. VHI showed negative progression from 6-months to 1-year post-injection, during which time the speaking fundamental frequency (SFF) changed to the high pitch in men.</div></div><div><h3>Conclusions</h3><div>Single high dose intracordal trafermin injections can be expected to improve voice in the early post-injection period and to maintain its effect for 1 year. SFF may play a role in worsening VHI in men.</div></div><div><h3>Level of evidence</h3><div>level 4.</div></div>","PeriodicalId":49954,"journal":{"name":"Journal of Voice","volume":"39 5","pages":"Pages 1368-1376"},"PeriodicalIF":2.4000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"One Year Outcomes and Longitudinal Changes in Voice Improvement With Single High Dose Intracordal Trafermin Injections for Age-Related Vocal Fold Atrophy\",\"authors\":\"Tomohiro Hasegawa , Takeharu Kanazawa , Daigo Komazawa , Ujimoto Konomi , Mayu Hirosaki , Yusuke Watanabe\",\"doi\":\"10.1016/j.jvoice.2023.03.017\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Objective</h3><div>Although intracordal trafermin injection has been performed in the treatment of age-related vocal fold atrophy, the effects of single high dose trafermin injections are unknown. In this study, we examined the 1 year outcomes and longitudinal changes in voice improvement with single high dose intracordal trafermin injections.</div></div><div><h3>Study Design</h3><div>Retrospective study with approval by our Ethics Committee.</div></div><div><h3>Methods</h3><div><span>The medical records of 34 patients who underwent single high dose (50ug per side) intracordal trafermin injections under </span>local anesthesia for vocal fold atrophy were retrospectively reviewed at 1 month pre-injection and 1 month, 6 months and 1 year post injection.</div></div><div><h3>Results</h3><div><span>Maximum phonation time (MPT), pitch range (PR), Japanese version of voice handicap index (VHI), grade of </span>GRBAS evaluation, and jitter% improved significantly at 1-year post-injection compared to 1-month pre-injection. MPT and PR improved as early as 1-month post-injection and continued to improve most at 1-year post-injection. VHI showed negative progression from 6-months to 1-year post-injection, during which time the speaking fundamental frequency (SFF) changed to the high pitch in men.</div></div><div><h3>Conclusions</h3><div>Single high dose intracordal trafermin injections can be expected to improve voice in the early post-injection period and to maintain its effect for 1 year. SFF may play a role in worsening VHI in men.</div></div><div><h3>Level of evidence</h3><div>level 4.</div></div>\",\"PeriodicalId\":49954,\"journal\":{\"name\":\"Journal of Voice\",\"volume\":\"39 5\",\"pages\":\"Pages 1368-1376\"},\"PeriodicalIF\":2.4000,\"publicationDate\":\"2025-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Voice\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0892199723001108\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"AUDIOLOGY & SPEECH-LANGUAGE PATHOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Voice","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0892199723001108","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"AUDIOLOGY & SPEECH-LANGUAGE PATHOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

目的：虽然脊髓内注射曲弗明已被用于治疗老年性声带萎缩，但单次大剂量曲弗明注射的效果尚不清楚。在这项研究中，我们检查了单次高剂量环内注射曲弗明的1年预后和语音改善的纵向变化。研究设计经伦理委员会批准的回顾性研究。方法回顾性分析34例局部麻醉下单次高剂量（每侧50ug）曲弗明注射治疗声带萎缩患者在注射前1个月、注射后1个月、6个月和1年的病历。结果注射后1年的最大发声时间（MPT）、音高范围（PR）、日文版语音障碍指数（VHI）、GRBAS评分等级和抖动%较注射前1个月有显著改善。MPT和PR早在注射后1个月改善，并在注射后1年继续改善最多。注射后6个月至1年，VHI呈负进展，在此期间，男性的说话基频（SFF）变为高音。结论单次高剂量曲弗明注射可在注射后早期改善声带，并可维持1年。SFF可能在男性VHI恶化中起作用。证据等级：4级。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

One Year Outcomes and Longitudinal Changes in Voice Improvement With Single High Dose Intracordal Trafermin Injections for Age-Related Vocal Fold Atrophy

Objective

Although intracordal trafermin injection has been performed in the treatment of age-related vocal fold atrophy, the effects of single high dose trafermin injections are unknown. In this study, we examined the 1 year outcomes and longitudinal changes in voice improvement with single high dose intracordal trafermin injections.

Study Design

Retrospective study with approval by our Ethics Committee.

Methods

The medical records of 34 patients who underwent single high dose (50ug per side) intracordal trafermin injections under local anesthesia for vocal fold atrophy were retrospectively reviewed at 1 month pre-injection and 1 month, 6 months and 1 year post injection.

Results

Maximum phonation time (MPT), pitch range (PR), Japanese version of voice handicap index (VHI), grade of GRBAS evaluation, and jitter% improved significantly at 1-year post-injection compared to 1-month pre-injection. MPT and PR improved as early as 1-month post-injection and continued to improve most at 1-year post-injection. VHI showed negative progression from 6-months to 1-year post-injection, during which time the speaking fundamental frequency (SFF) changed to the high pitch in men.

Conclusions

Single high dose intracordal trafermin injections can be expected to improve voice in the early post-injection period and to maintain its effect for 1 year. SFF may play a role in worsening VHI in men.

Level of evidence

level 4.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of Voice 医学-耳鼻喉科学

CiteScore

4.00

自引率

13.60%

发文量

395

审稿时长

59 days

期刊介绍： The Journal of Voice is widely regarded as the world''s premiere journal for voice medicine and research. This peer-reviewed publication is listed in Index Medicus and is indexed by the Institute for Scientific Information. The journal contains articles written by experts throughout the world on all topics in voice sciences, voice medicine and surgery, and speech-language pathologists'' management of voice-related problems. The journal includes clinical articles, clinical research, and laboratory research. Members of the Foundation receive the journal as a benefit of membership.